Company intelligence
EntityRisk
Optimizing price, evidence investments, and value communication with leading expertise and advanced predictive software.
About EntityRisk
EntityRisk redefines drug value assessment and evidence planning with a fast, transparent, predictive software solution powered by renowned health economics, policy, and data science expertise — giving clients advanced tools to choose justifiable prices, inform evidence investments, and communicate and win on value. EntityRisk's PROVEN™ software replaces fragmented and static Excel-based disease models with a unified and dynamic Python software environment. This enables the generation of rigorous and centralized core disease models in the background earlier in the product development lifecycle with clear, simple, and interactive visual results on the front end. PROVEN™ enables the parallel execution of various predictive models and value frameworks along with the simultaneous analysis of RCT and real-world data. This sophisticated capability enables teams to: - Predict outcomes, comparative effectiveness, and price. - Quantify, define, and communicate value. - Inform evidence prioritization and investments across the pipeline portfolio - Generate BIMs and CEMs for customer interaction and HTA submission - Inform CMS Negotiations, MFN planning, Launch Sequencing and OBCs
Verified activity
Signals from EntityRisk
2 published signals
People
EntityRisk hired Ye Shen as a Research Scientist with expertise in simulation modeling, health policy, and health economics and outcomes research.
Reported by EntityRisk
Research & Knowledge
EntityRisk published an article for ISPOR's Value & Outcomes Spotlight demonstrating a path forward using shrinkage priors and Bayesian model averaging to borrow strength from historical trial data and real-world data for rare disease functional status prediction
Reported by EntityRisk